Editorial: III Bio.Natural-bioactive natural products research meeting: pharmacology perspectives.

Front Pharmacol

Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.

Published: November 2024

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614142PMC
http://dx.doi.org/10.3389/fphar.2024.1517673DOI Listing

Publication Analysis

Top Keywords

editorial iii
4
iii bionatural-bioactive
4
bionatural-bioactive natural
4
natural products
4
products meeting
4
meeting pharmacology
4
pharmacology perspectives
4
editorial
1
bionatural-bioactive
1
natural
1

Similar Publications

Unveiling Targets and Resistance in FGFR-Altered Cancers.

Ann Oncol

January 2025

Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich; 2German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:

View Article and Find Full Text PDF

Differential Inhibition by Cenobamate of Canonical Human Nav1.5 Ion Channels and Several Point Mutants.

Int J Mol Sci

January 2025

Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania.

Cenobamate is a new and highly effective antiseizure compound used for the treatment of adults with focal onset seizures and particularly for epilepsy resistant to other antiepileptic drugs. It acts on multiple targets, as it is a positive allosteric activator of γ-aminobutyric acid type A (GABA) receptors and an inhibitor of neuronal sodium channels, particularly of the late or persistent Na current. We recently evidenced the inhibitory effects of cenobamate on the peak and late current component of the human cardiac isoform hNav1.

View Article and Find Full Text PDF

Consolidation ALK Tyrosine Kinase Inhibitor in Definitively Treated Unresectable Stage III ALK+ NSCLC: Can Real-World Data Inform Clinical Decision in the Absence of a LAURA-Type Designed Trial?

J Thorac Oncol

January 2025

Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange/Irvine, California; Chao Family Comprehensive Cancer Center, Orange/Irvine, California; St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:

View Article and Find Full Text PDF

Objectives: To describe and enumerate surgeries for patients who underwent reconstruction or amputation after severe distal tibia, ankle, and mid to hindfoot injuries.

Methods: Design: Secondary analysis of a multicenter prospective observational study.

Setting: 31 U.

View Article and Find Full Text PDF

Right ventricular (RV) dysfunction after biventricular repair is critical in most adults with congenital heart disease (ACHD). Conventional 2D magnetic resonance imaging (MRI) measurement is considered as a 'gold standard' for RV evaluation; however, addition information on ACHD after biventricular repair is sometimes required. The reasons why adjunctive information is required is as follows: (I) to evaluate the severity of cardiac burden in symptomatic patients with normal RV size and ejection fraction (EF), (II) to determine the optimal timing of invasive treatments in asymptomatic ones, and (III) to detect proactively a potential cardiac burden leading to ventricular deterioration, from a fluid dynamics perspective.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!